ClinicalTrials.gg
Status unknownNCT03080441Updated Mar 15, 2017

Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention

A Phase 4 interventional study of pressure stockings and Midodrine in Intradialytic Hypotension, sponsored by Nimedical. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Nimedical · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2017), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing midodrine in Hypotension — 4 open to participants now, 4 under way, 1 of them phase 3. Midodrine · Hypotension.

Planned enrollment
9th of 12
35 · median 62
Started
2016
the only one that year
Phase 4
4 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
Nimedical

Among the 12 studies testing midodrine in Hypotension, this one is the 9th largest by planned enrollment, is the only one that started in 2016, is one of 4 in phase 4, and was the 6th registered.

Hypotension

887 studies on the registry are indexed under Hypotension; 196 are open to participants now.

Browse Hypotension studies →

Open to participants now

4 of the 12 studies testing midodrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About midodrine

Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Hypotension studies recruiting now, 50 (45%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing midodrine in Hypotension, or all of them as a file.
02

Study summary

This is a research study to test the application of FDA-approved, non-invasive device (NICaS) that measure the performance of your heart during HD treatment.

Read the detailed description

The incidence of intradialytic hypotension (IDH) events, reported to occur in 15% to 50% of hemodialysis (HD) treatments, is still high despite major technical advances in HD technology. By definition, excessive reduction in intravascular volume by ultrafiltration and limited vascular refilling from tissues into the vascular space is the cause of IDH. Chronic HD patients exhibit a high prevalence of peripheral vascular and cardiac abnormalities. Specifically, hemodynamic instability during HD can occur due to insufficient reduction in venous unstressed volume, poor diastolic filling under reduced atrial pressures associated with diastolic dysfunction, altered cardiac contractility, and impaired vascular reactivity. An IDH event can lead to myocardial cerebral and other organ ischemia. Long- and short-term adverse outcomes have been associated with IDH, a common HD complication and significant cause of morbidity.

Recent pilot studies suggest that in IDH-prone subjects, measurements of hemodynamic variables during HD can be used to categorize the hemodynamic response into three subgroups: cardiac power index (CPI) reduction with stable total peripheral resistance (TPR), TPR reduction with stable CPI, and reduction in TPR and CPI groups. It is hypothesized that targeted intervention for each subgroup can reduce IDH.

03

Conditions studied

  • Intradialytic Hypotension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or older
  • Have been on maintenance hemodialysis at the facility for at least six months
  • Have not had un-excused missed treatments for six months
  • Is symptomatic to HD treatments
  • Males and non-pregnant/non-nursing females, as confirmed via urine pregnancy testing of women of child bearing potential

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Currently on Midodrine at the start of the Phase 1, Observation period
  • Any known to Midodrine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Phase 1 Group 1

    pressure stockings worn during dialysis treatment

    Device: pressure stockings

  • Experimental
    Phase 1 Group 2

    Midodrine before dialysis treatment

    Drug: Midodrine

  • Experimental
    Phase 1 Group 3

    pressure stocking and Midodrine

    Other: pressure stockings and midodrine

Interventions

  • Devicepressure stockings

    pressure stockings worn during dialysis throughout treatment period

  • administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.

  • Otherpressure stockings and midodrine

    combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period

06

What researchers measure

Primary outcomes

  1. Hypotension

    Post dialysis BP measured in mm/Hg

    Time frame: 6 weeks

  2. Weight

    Post dialysis weight measure in kg

    Time frame: 6 weeks

  3. Cardiac Index

    Cardiac Index results from NICaS results vs Echocardiogram results measured in L/min/m2

    Time frame: 1 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is no current plan to share IPD with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2016 (actual). Primary completion is estimated for Apr 2017, 4 months after the start.

Of 61 phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2017
First posted
Mar 15, 2017
StartActual
Nov 11, 2016
Primary completionEst.
Apr 1, 2017
CompletionEst.
May 1, 2017
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03080441
Lead sponsor
Nimedical
Responsible party
Sponsor
First posted
Mar 15, 2017
Start date
Nov 11, 2016
Primary completion
Apr 1, 2017 (estimated)
Completion
May 1, 2017 (estimated)
Last update
Mar 15, 2017

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion